Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

3.62
+0.12003.43%
Post-market: 3.53-0.0900-2.49%19:45 EDT
Volume:1.16M
Turnover:4.17M
Market Cap:246.65M
PE:-3.54
High:3.69
Open:3.50
Low:3.41
Close:3.50
Loading ...

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

GlobeNewswire
·
24 Apr

Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?

Insider Monkey
·
23 Apr

BRIEF-Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors

Reuters
·
10 Apr

Corvus Pharmaceuticals Appoints New Director to Board

TIPRANKS
·
10 Apr

Corvus Pharmaceuticals Appoints Richard a. Van Den Broek to Board of Directors

THOMSON REUTERS
·
10 Apr

Press Release: Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Dow Jones
·
10 Apr

Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges

TIPRANKS
·
27 Mar

Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Dow Jones
·
27 Mar

Q4 2024 Corvus Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
26 Mar

Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit

Simply Wall St.
·
26 Mar

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating

MT Newswires Live
·
26 Mar

Corvus Pharmaceuticals : Oppenheimer Raises Target Price to $15 From $14

THOMSON REUTERS
·
26 Mar

Corvus Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Mar

Analysts Are Bullish on These Healthcare Stocks: Artiva Biotherapeutics, Inc. (ARTV), Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
26 Mar

Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
26 Mar

Corvus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Mar

Corvus Pharmaceuticals: Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 to Be Presented in May

THOMSON REUTERS
·
26 Mar

Corvus Pharmaceuticals Q4 Operating Expenses USD 8.105 Million

THOMSON REUTERS
·
26 Mar

Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
22 Mar

Corvus announces presentation of data from Phase 1/1b trial of soquelitinib

TIPRANKS
·
20 Mar